Proceedings of the National Academy of Sciences · 2005 · 132 citations · 32 references
Life SciencesMolecular BiologyDna ReplicationMolecular VirologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral TherapyNucleos(t)ide Analog TherapyRna DecayRna Polymerase FunctionDna Synthesis InhibitionDrug Resistance MutationsNucleoside AnalogsNucleoside Analogue ResistanceNucleoside Reverse Transcriptase InhibitorsResistance-suppressing MutationsReverse Transcriptase Inhibitor ResistanceViral Rna Template Switching
Understanding the mechanisms of HIV-1 drug resistance is critical for developing more effective antiretroviral agents and therapies. Based on our previously described dynamic copy-choice mechanism for retroviral recombination and our observations that nucleoside reverse transcriptase inhibitors (NRTIs) increase the frequency of reverse transcriptase template switching, we propose that an equilibrium exists between (i) NRTI incorporation, NRTI excision, and resumption of DNA synthesis and (ii) degradation of the RNA template by RNase H activity, leading to dissociation of the template-primer and abrogation of HIV-1 replication. As predicted by this model, mutations in the RNase H domain that reduced the rate of RNA degradation conferred high-level resistance to 3'-azido-3'-deoxythymidine and 2,3-didehydro-2,3-dideoxythymidine by as much as 180- and 10-fold, respectively, by increasing the time available for excision of incorporated NRTIs from terminated primers. These results provide insights into the mechanism by which NRTIs inhibit HIV-1 replication and imply that mutations in RNase H could significantly contribute to drug resistance either alone or in combination with NRTI-resistance mutations in reverse transcriptase.
32
Luigi Naldini, Ulrike Blömer, Fred H. Gage et al. · Proceedings of the National Academy of Sciences · 1996 · 1.5K citations · Full text
J K Yee, Atsushi Miyanohara, Patricia LaPorte et al. · Proceedings of the National Academy of Sciences · 1994 · 492 citations